Deterioration in parkinsonism with low-dose pergolide

Journal of Neurology

Volumn 246, Issue 4, 1999, Pages 309-311

  Kellett, Mark W ^a   Steiger, Malcolm J ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Dopamine agonist; Dopamine autoreceptor; Pergolide; Pre synaptic dopamine receptor

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE; DOPAMINE AUTORECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DETERIORATION; DISEASE COURSE; DRUG EFFICACY; DYSKINESIA; HUMAN; MALE; NAUSEA; PARKINSONISM; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PARKINSON DISEASE; PERGOLIDE; RECEPTORS, DOPAMINE;

EID: 0032917718     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150050352     Document Type: Article

References (18)

1. 1. Marsden CD, Parkes J, Quinn N (1982) Fluctuations of disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth Scientific, London, pp 96
2. 2. Tolosa E, Blesa R, Bayes A, Forcadell F (1987) Low-dose bromocriptine in the early phases of Parkinson's disease. Clin Neuropharmacol 10:169-174
3. 3. Rinne U (1987) Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5 year follow-up. Neurology 37:826-828
4. 4. Olanow CW (1997) Rationale for dopamine agonists in early Parkinson's disease therapy. In: Olanow CW, Obeso JA (eds) Beyond the decade of the brain, vol 2. Wells Medical, Royal Tunbridge Wells, pp 37-55
5. 5. Goetz C, Tanner C, Glantz F, Klawans H (1985) Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 35:749-751
6. 6. Yanagisawa N, Kanazawa I, Goto I, et at (1994) Seven-year follow-up study of bromocriptine therapy for Parkinson's disease. Eur Neurol 34 [Suppl 3]:S29-S35
7. 7. Stem G, Lees A (1983) Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease. Adv Neurol 37:17-21
8. 8. Montrastruc J, Rascol O, Rascol A (1989) A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 52:773-775
9. 9. Felten D, Felten S, Fuller R, et at (1992) Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fisher-344 rats. Neurobiol Aging 13:339-351
10. 10. Di Chiara G, Porceddu ML, Vargui L, Stefanini E, Gessa G (1977) Evidence for selective and long-lasting stimulation of 'regulatory' dopamine receptors by bromocriptine. Archives of Pharmacology 300:239-245
11. 11. Jiang D, Reches A, Wagner H, Fahn S (1984) Biochemical and behavioural evaluation of pergolide as a dopamine agonist in the rat brain. Neuropharmacology 23:295-301
12. 12. Tissari AH, Rosetti ZL, Meloni M, Frau MI, Gessa GI (1983) Autoreceptors mediate the inhibition of dopamine synthesis by bromocriptine and lisuride in rats. Eur J Pharmacol 91:463-468
13. 13. Roth R (1984) CNS dopamine autoreceptors: distribution, pharmacology and function. Ann NY Acad Sci 35: 2281-2296
14. 14. Seeman P, Van Tol HHM (1993) Dopamine receptor pharmacology. Current opinion in Neurology and Neurosurgery 6:602-608
15. 15. Onali P, Mosca E, Olianas M (1992) Presynaptic dopamine autoreceptors and second messengers controlling tyrosine hydroxylase activity in rat brain. Neurochem Int 20:89S-93S
16. 16. Bunney B, Walters J, Roth R, Aghajanian G (1973) Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:560-571
17. 17. Walkinshaw G, Waters C (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-dopa: implications for the treatment of Parkinson's disease. J Clin Invest 95:2458-2464
18. 18. Blunt S, Jenner P, Marsden C (1993) Suppressive effects of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 8:129-133